Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin combinations in RRMM (DREAMM-6)
NCT03544281Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Sep 2018; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03544281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544281.